Categories
-Top News India News

Over 1 lakh crore allocated to DRDO for modernization of defence

The Minister informed the House that this is an increase of Rs 21, 415.41crore (23.78%) over BE 2020-21 allocations…reports Asian Lite News.

The Defence Research and Development Organization (DRDO) has been allocated over 1 lakh crore to boost development of state-of-the-art platforms, weapon systems and sensors in the country, Minister of State for Defence Ajay Bhatt told the Rajya Sabha in a written reply on Monday.

An amount of Rs 1,11,463.21 crore has been allocated under the Capital Acquisition Head (Modernisation) of Defence Services in BE 2021-22, he said.

The Minister informed the House that this is an increase of Rs 21, 415.41crore (23.78%) over BE 2020-21 allocations.

He further informed that DRDO has taken projects, for development of Products/Systems, in various technology domains.

Some of them are Missiles Systems, Airborne Early Warning & Surveillance, Fighter Aircrafts, Armoured Fighting Vehicles, Bridging and Mining Systems, Guided Munitions, Artillery Guns & Rockets, Small Arms & Ammunitions, Advanced Torpedoes & Advanced Sonar Suite, Electronic Warfare (EW), Long Range Radars, and Artificial Intelligence based Systems among others.

Under the Make in India project, the Minister informed that many significant projects including 155mm Artillery Gun system ‘Dhanush’, Bridge Laying Tank, Light Combat Aircraft ‘Tejas’, ‘Akash’ Surface to Air Missile system, Submarine ‘INS Kalvari’, Inshore Patrol Vessel, Offshore Surveillance Ship, ‘INS Chennai’, Anti-Submarine Warfare Corvette (ASWC), Arjun Armoured Repair and Recovery Vehicle, Landing Craft Utility, Bridge Laying Tank, Bi-Modular Charge System (BMCS) for 155mm Ammunition, Thermal Imaging Sight Mark-II for T-72 tank, 25 T Tugs, Water Jet Fast Attack Craft, Offshore Patrol Vessel, Fast Interceptor Boat, INS Kalvari, INS Khanderi, Medium Bullet Proof Vehicle (MBPV), Lakshya Parachute for Pilotless Target Aircraft, etc. have been produced in last few years.

Further, the Minister said that the central government has taken several policy initiatives and brought reforms to promote self-reliance in defence manufacturing. These policy initiatives are aimed at encouraging indigenous design, development and manufacture of defence equipment in the country, thereby reducing dependency on imports in the long run.

Listing the policy initiatives, the Minister in the reply to the Upper House of the parliament, said that DPP-2016 has been revised as Defence Acquisition Procedure (DAP)- 2020, which is driven by the tenets of Defence Reforms announced as part of ‘Aatmanirbhar Bharat Abhiyan’.

He noted that in order to promote indigenous design and development of defence equipment ‘Buy {Indian-IDDM (Indigenously Designed, Developed and Manufactured)}’ category has been accorded top most priority for procurement of capital equipment.

Further, the Minister highlighted that the Ministry of Defence has notified two ‘Positive indigenisation lists’ of 209 items for which there would be an embargo on the import beyond the timeline indicated against them. This would offer a great opportunity to the Indian defence industry to manufacture listed items using their own design and development capabilities to meet the requirements of the Indian Armed Forces, he said.

He said that the ‘Make’ Procedure of capital procurement has been simplified. There is a provision for funding upto 70% of development cost by the Government to Indian industry under Make-IN category. In addition, there are specific reservations for MSMEs under the ‘Make’ procedure.

Procedure for ‘Make-II’ category (Industry funded), introduced in DPP-2016 to encourage indigenous development and manufacture of defence equipment has a number of industry friendly provisions such as relaxation of eligibility criterion, minimal documentation, provision for considering proposals suggested by industry /individual etc. So far, 58 projects relating to Army, Navy & Air Force, have been accorded ‘Approval in Principle’, the Minister said.

The Minister recalled that the Government has approved enhanced delegation of Financial Powers under Capital Procurement to levels below the Vice-Chief of Armed Forces in February, 2021. The Government has also approved enhanced delegation of Financial Powers in the Make-I category under which public funding up to 70% of the prototype development cost is available for Design & Development of equipment, systems, major platforms or upgrades thereof.

The Government of India has enhanced FDI in Defence Sector up to 74% through the Automatic Route and up to 100% by the Government Route wherever it is likely to result in access to modern technology or for other reasons to be recorded.

He told the House that the government has established two Defence Industrial Corridors, one each in Uttar Pradesh and Tamil Nadu. The investments of Rs 20,000 Cr are planned in Defence corridors of Uttar Pradesh and Tamil Nadu by year 2024.

So far, investment of approx. Rs 3342 crore have been made in both the corridors by public as well private sector companies. Moreover, the respective State Governments have also published their Aerospace & Defence Policies to attract private players as well as foreign companies including Original Equipment Manufacturers (OEMs) in these two corridors.

An Inter-Governmental Agreement (IGA) on “Mutual Cooperation in Joint Manufacturing of Spares, Components, Aggregates and other material related to Russian/Soviet Origin Arms and Defence Equipment” was signed in September, 2019.

The objective of the IGA is to enhance the “After Sales Support” and operational availability of Russian origin equipment currently in service in Indian Armed Forces by organizing production of spares and components in the territory of India by Indian Industry by way of creation of Joint Ventures/Partnership with Russian Original Equipment Manufacturers (OEMs) under the framework of the “Make in India” initiative.

Defence Products list requiring Industrial License has been rationalised and manufacture of most of parts or components does not require Industrial License. The initial validity of the Industrial Licence granted under the IDR Act has been increased from 03 years to 15 years with a provision to further extend it by 03 years on a case-to-case basis.

The Minister said that the Department of Defence Production has notified 46 items under the latest Public Procurement Order 2017 notified by Department for Promotion of Industry and Internal Trade (DPIIT), for which there is sufficient local capacity and competition and procurement of these items shall be done from local suppliers only irrespective of the purchase value.

Defence Investor Cell (DIC) was created in February 2018 in the Ministry to provide all necessary information including addressing queries related to investment opportunities, procedures and regulatory requirements for investment in the sector. So far, 1182 queries have been addressed by DIC, the minister said in his reply.

ALSO READ-On goodwill visit to UAE, IAF Chief looks to further strengthen defence ties

READ MORE-Indian industries got 60% of total defence contracts: Govt

Categories
-Top News India News

India successfully flight-tests man-portable anti-tank guided missile

Defence Minister Rajnath Singh has congratulated DRDO and the industry for the successful test…reports Asian Lite News.

India successfully flight-tested its indigenously developed low weight, fire and forget man-portable anti-tank guided missile (MPATGM) on Wednesday.

The step is seen as a major boost to ‘AatmaNirbhar Bharat’ (Self Reliant India) and strengthening the Indian Army.

The missile was developed by the Defence Research and Development Organisation (DRDO). The missile was launched from a man-portable launcher integrated with thermal site and the target was mimicking a tank.

The missile hit the target in direct attack mode and destroyed it with precision. The test has validated the minimum range successfully.

“All the mission objectives were met. The missile has already been successfully flight tested for the maximum range,” DRDO said in a statement.

The missile is incorporated with state-of-the-art miniaturised infrared imaging seeker along with advanced avionics.

The test brings the development of indigenous third-generation man-portable Anti-Tank Guided Missile close to completion.

Defence Minister Rajnath Singh has congratulated DRDO and the industry for the successful test.

On Tuesday, DRDO had indigenously developed a High Strength Metastable Beta Titanium Alloy that can be used in forging aerospace structures. The metal contains Vanadium, Iron and Aluminium.

These alloys are already being used by many developed nations in recent times as a beneficial substitute for the relatively heavier traditional Nickel-Chromium-Molybdenum structural steels, to achieve weight savings.

According to DRDO, the high strength beta titanium alloys are unique due to their higher strength, ductility, fatigue, and fracture toughness making them increasingly attractive for aircraft structural applications.

ALSO READ-DRDO fired A-SAT missile off Abdul Kalam Island

READ MORE-DRDO’s anti-COVID drug approved for emergency use

Categories
COVID-19 India News

DRDO’s anti-COVID drug approved for emergency use

Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence…reports Asian Lite News.

The Drugs Controller General of India has approved an anti-COVID-19 drug developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS) for emergency use, the Defence Ministry has said.

An anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by INMAS, a lab of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.

Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.

A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients. The drug will be of immense benefit to the people suffering from Covid-19.

“Pursuing Prime Minister Narendra Modi’s call for preparedness against the pandemic, DRDO took the initiative of developing anti-COVID therapeutic application of 2-DG,” the ministry said in a statement on Friday.


A health worker inoculates a Man with a dose of the Covishield vaccine against the Covid-19 coronavirus at a school temporary converted into a vaccination center, in New Delhi on India  May 03, 2021 (Pallav Paliwal)

In April 2020, during the first wave of the pandemic, INMAS-DRDO scientists conducted laboratory experiments with the help of the Centre for Cellular and Molecular Biology (CCMB), Hyderabad and found that this molecule works effectively against the SARS-CoV-2 virus and inhibits the viral growth.

Based on these results, the Drugs Controller General of India’s (DCGI) Central Drugs Standard Control Organization (CDSCO) permitted the Phase-II clinical trial of 2-DG in COVID-19 patients in May 2020.

The DRDO, along with its industry partner DRL, Hyderabad, started clinical trials to test the safety and efficacy of the drug in COVID-19 patients.

In Phase-II trials (including dose-ranging) conducted from May to October 2020, the drug was found to be safe in Covid-19 patients and showed significant improvement in their recovery.

Phase-IIa was conducted in six hospitals and Phase IIb (dose-ranging) clinical trial was conducted at 11 hospitals all over the country. The Phase-II trial was conducted on 110 patients.

A medical worker prepares a dose of the Covishield vaccine against the Covid-19 coronavirus at a school temporary converted into a vaccination center, in New Delhi on India. (Pallav Paliwal)

Inefficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints.

“A significantly favorable trend (2.5 days difference) was seen in terms of the median time to achieving normalization of specific vital signs parameters when compared to SoC,” the ministry said.

Based on successful results, the DCGI further permitted the Phase-III clinical trials in November 2020.

The Phase-III clinical trial was conducted on 220 patients between December 2020 to March 2021 at 27 Covid hospitals in Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu. The detailed data of the Phase-III clinical trial was presented to the DCGI.


 A health worker inoculates a Man with a dose of the Covishield vaccine against the Covid-19 coronavirus at a school temporary converted into a vaccination center, in New Delhi on India  May 03, 2021 (Pallav Paliwal)

“In 2-DG arm, a significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by Day-3 in comparison to SoC, indicating an early relief from Oxygen therapy/dependence,” the ministry stated.

A similar trend was observed in patients aged more than 65 years.

On May 1, 2021, the DCGI granted permission for the Emergency Use of this drug as an adjunct therapy in moderate to severe COVID-19 patients.

Also Read-‘Pfizer-BioNTech vax very effective against UK, SA variants’

Read More-Switzerland sends medical aid to India

Categories
COVID-19

DRDO develops oxygen delivery system

Hypoxia is a state in which the amount of oxygen reaching the tissues is inadequate to fulfill all the energy requirements of the body. This is exactly the situation that gets replicated in a Covid patient due to the virus infection and has been a leading factor in the current crisis…reports Asian Lite News.

Defence Research and Development Organisation (DRDO) has developed SpO2 (Blood Oxygen Saturation) supplemental Oxygen Delivery System for soldiers posted at extreme high-altitude areas.

Developed by Defence Bio-Engineering & ElectroMedical Laboratory (DEBEL), Bengaluru of DRDO, the system delivers supplemental oxygen based on the SpO2 levels and prevents the person from sinking in to a state of Hypoxia, which is fatal in most cases, if sets in. This automatic system can also prove to be a boon during the current Covid-19 situation.

Hypoxia is a state in which the amount of oxygen reaching the tissues is inadequate to fulfill all the energy requirements of the body. This is exactly the situation that gets replicated in a Covid patient due to the virus infection and has been a leading factor in the current crisis.

The electronic hardware of the system is designed for functioning at extreme altitudes featuring low barometric pressures, low temperatures and humidity. The software safety checks incorporated into the system are critical in ensuring the functional reliability of the system in field conditions.

The system reads SpO2 levels of the subject from a wrist-worn pulse oximeter module through wireless interface and controls a proportional solenoid valve to regulate the oxygen supply to the subject. The oxygen is delivered from a lightweight portable oxygen cylinder through nasal nares.

The system is available in various sizes from one litre and one kg weight with 150 litres of oxygen supply to 10 litres & 10 kg weight with 1,500 litres of oxygen supply which can sustain for 750 minutes with a continuous flow of two liters per min (lpm).

Since the system is indigenously developed for operation in field conditions, it is unique with its dual qualities of being robust & cheap and is already in bulk production with the industry.

The system is a boon in the current pandemic as it can be used in the household for moderate Covid patients for Oxygen flow therapy with flow controlled at 2/5/7/10 lpm flow. The automatic usage has a huge advantage in the household, as the oximeter would give an alarm for lower SpO2 value.

It will automatically increase/decrease the O2 flow based on SpO2 setting which can be auto adjusted at 2, 5, 7, 10 lpm flow rate. The optimal O2 flow rate conserves the O2 resources/O2 management and greatly increases the endurance.

With its availability and simple to use facility by a common person, the system shall greatly reduce the workload and exposure time of doctors and paramedics to monitor the SpO2 levels of the patient. The automated Calibrated Variable Flow Control for Low O2 levels (User preset, <90%, <80%) through a calibrated Flow Control Valve (PFCV) will facilitate in economising the oxygen supply (1-10 lpm with ±0.5 lpm). A moderate Covid patient requires long term moderate O2 supply 10Litre/150bar–10kg–1500 litres which can sustain up to 750 minutes.

This automated, easy to use Oxygen Delivery System now available is a great boon particularly in these critical times when medical resources are stretched to their limits. Its proliferation would mitigate the crisis in management of such a huge number of Covid patients in many ways all across the country.

Also Read-Lockdown only the last resort: Modi

Read More-Oxygen Supply Firm’s Contract Ended in March